Reddy’s Exclusivity End Allows Teva, Natco To Match Full US Revlimid Suite
Controversial BMS Brand, Generics Challenged In Ongoing US Antitrust Suit
Teva has moved fast to match Dr Reddy’s Laboratories’ complete six-strength offering of generic Revlimid (lenalidomide) products in the US.
You may also be interested in...
Cipla, Dr Reddy’s, Viatris And Teva Named In US Revlimid Antitrust Suit
Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.
Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US
Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.
Teva Pounces On US Revlimid Opportunity With Four Strength-Offering
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.